Search by Drug Name or NDC
NDC 72789-0213-98 Abiraterone 250 mg/1 Details
Abiraterone 250 mg/1
Abiraterone is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by PD-Rx Pharmaceuticals, Inc.. The primary component is ABIRATERONE ACETATE.
MedlinePlus Drug Summary
Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
Related Packages: 72789-0213-98Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Abiraterone
Product Information
NDC | 72789-0213 |
---|---|
Product ID | 72789-213_06348ed6-e295-6b48-e063-6294a90a4074 |
Associated GPIs | 21406010200320 |
GCN Sequence Number | 067349 |
GCN Sequence Number Description | abiraterone acetate TABLET 250 MG ORAL |
HIC3 | V1J |
HIC3 Description | ANTINEOPLASTIC - ANTIANDROGENIC AGENTS |
GCN | 29886 |
HICL Sequence Number | 037571 |
HICL Sequence Number Description | ABIRATERONE ACETATE |
Brand/Generic | Generic |
Proprietary Name | Abiraterone |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Abiraterone acetate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 250 |
Active Ingredient Units | mg/1 |
Substance Name | ABIRATERONE ACETATE |
Labeler Name | PD-Rx Pharmaceuticals, Inc. |
Pharmaceutical Class | Cytochrome P450 17A1 Inhibitor [EPC], Cytochrome P450 17A1 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA208339 |
Listing Certified Through | 2024-12-31 |
Package
NDC 72789-0213-98 (72789021398)
NDC Package Code | 72789-213-98 |
---|---|
Billing NDC | 72789021398 |
Package | 120 TABLET in 1 BOTTLE, PLASTIC (72789-213-98) |
Marketing Start Date | 2021-10-11 |
NDC Exclude Flag | N |
Pricing Information | N/A |